OBJECTIVE To report the presentation, clinical course and prognosis of myasthenia gravis (MG) with thyroid disease. METHODS Retrospective data analysis was conducted.Between 2004 and 2013, we reviewed a total of 106 patients with MG. We analyzed the clinical features, the relationship between the thyroid function, antibodies and the clinical course, prognosis. RESULTS (1) In our study, 20/106 (18.87%) patients were thyroid function-abnormal, 37/106 (34.91) were thyroglobulin antibodies (TGAb) and/or thyroid microsomal antibody (TMAb)-positive, and abnormality was observed in 46 (43.40%) of the thyroid gland. Thyroid antibody positive rate was higher than abnormal thyroid function rate, and the difference was significant (P=0.036). (2) The thyroid stimulating hormone (TSH) level ((2.9±4.0) mIU/L) of ocular MG was higher than the level ((1.5±1.1) mIU/L) of generalized MG (P=0.01). (3) The transformation time of 52 ocular type to generalized type was longer in higher antibody group than in normal group (P=0.04). And there were no significant differences between the elevated TSH type and the normal TSH type, the abnormal thyroid function type and normal thyroid function type, the abnormal thyroid type and the normal thyroid type. (4) Comparing the TSH level, total antibody level, TGAb, and TMAb level between the ease group and the unease group in the course of 1 year, 2 years, 5 years, there were no significant differences (all P>0.05). CONCLUSIONS MG is often companied with thyroid abnormalities. MG patients are more susceptible to hashimoto thyroiditis and other autoimmune thyroid diseases. Ocular type patients are more likely to suffer from thyroid function decrease than the generalized type. MG patients with hashimoto thyroiditis and other autoimmune thyroid diseases are more sensitive to respond to therapy means like glucocorticoid therapy, and the short-term prognosis is relatively good. There are no significant correlations between the MG remission rate and TSH level, total antibody level, TGAb and TMAb level.

中文翻译：

---

重症肌无力合并甲状腺疾病106例的临床特征

目的报告重症肌无力（MG）合并甲状腺疾病的表现，临床病程和预后。方法进行回顾性数据分析.2004年至2013年间，我们共检查了106例MG患者。我们分析了临床特征，甲状腺功能，抗体与临床病程，预后之间的关系。结果（1）在我们的研究中，甲状腺功能异常的患者为20/106（18.87％），甲状腺球蛋白抗体（TGAb）和/或甲状腺微粒体抗体（TMAb）阳性的患者为37/106（34.91），并观察到异常在46个（43.40％）甲状腺中。甲状腺抗体阳性率高于异常甲状腺功能率，差异有统计学意义（P = 0.036）。（2）眼部MG的甲状腺刺激激素（TSH）水平（（2.9±4.0）mIU / L）高于水平（（1.5±1。1）广义MG的mIU / L）（P = 0.01）。（3）较高抗体组的52眼型向全身型的转化时间比正常组长（P = 0.04）。TSH升高型与正常TSH型，甲状腺功能异常与正常甲状腺功能型，甲状腺异常与正常甲状腺型之间无显着性差异。（4）比较缓解组和不安组在1年，2年，5年的TSH水平，总抗体水平，TGAb和TMAb水平，差异无统计学意义（均P> 0.05）。结论MG常伴有甲状腺异常。MG患者更容易患桥本甲状腺炎和其他自身免疫性甲状腺疾病。眼型患者比全身型患者更有可能患甲状腺功能下降。MG患有桥本甲状腺炎和其他自身免疫性甲状腺疾病的患者对糖皮质激素治疗等治疗手段的反应更为敏感，并且短期预后相对较好。MG缓解率与TSH水平，总抗体水平，TGAb和TMAb水平之间无显着相关性。